United States - English - NLM (National Library of Medicine)

bausch & lomb incorporated - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol 5 mg in 1 ml - albuterol sulfate inhalation solution is indicated for the relief of bronchospasm in patients 2 years of age and older with reversible obstructive airway disease and acute attacks of bronchospasm. albuterol sulfate inhalation solution is contraindicated in patients with a history of hypersensitivity to albuterol or any of its components.

United States - English - NLM (National Library of Medicine)

dr. reddy’s laboratories, inc. - levalbuterol (unii: edn2nbh5ss) (levalbuterol - unii:edn2nbh5ss) - levalbuterol 0.31 mg in 3 ml - levalbuterol inhalation solution, usp is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. levalbuterol inhalation solution is contraindicated in patients with a history of hypersensitivity to levalbuterol or racemic albuterol. reactions have included urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema [see warnings and precautions (5.6) ].   teratogenic effects: pregnancy category c . there are no adequate and well-controlled studies of levalbuterol inhalation solution in pregnant women. because animal reproduction studies are not always predictive of human response, levalbuterol inhalation solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. during worldwide marketing experience, various congenital anomalies, including cleft palate and limb defects, have been reported in newborns of women treated with racemi

United States - English - NLM (National Library of Medicine)

prasco laboratories - levalbuterol hydrochloride (unii: wdq1526qjm) (levalbuterol - unii:edn2nbh5ss) - levalbuterol 0.31 mg in 3 ml - levalbuterol hcl inhalation solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. levalbuterol hcl inhalation solution is contraindicated in patients with a history of hypersensitivity to levalbuterol or racemic albuterol. reactions have included urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema [see warnings and precautions (5.6) ]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to asthma medication, including levalbuterol hcl inhalation solution, during pregnancy. to enroll in mothertobaby pregnancy studies' asthma & pregnancy study or for more information about the registry, call 1-877-311-8972 or visit www.mothertobaby.org/ongoing-study/asthma. risk summary there are no adequate and well-controlled studies of levalbuterol hcl inhalation solution in pregnant women. there are clinical con

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - levalbuterol tartrate (unii: ads4i3e22m) (levalbuterol - unii:edn2nbh5ss) - levalbuterol 45 ug - levalbuterol tartrate hfa inhalation aerosol is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 4 years of age and older with reversible obstructive airway disease. levalbuterol tartrate hfa inhalation aerosol is contraindicated in patients with a history of hypersensitivity to levalbuterol, racemic albuterol, or any other component of levalbuterol tartrate hfa inhalation aerosol. reactions have included urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema. risk summary there are no adequate and well-controlled studies of levalbuterol tartrate hfa inhalation aerosol in pregnant women.  there are clinical considerations with the use of levalbuterol tartrate hfa inhalation aerosol in pregnant women [see clinical considerations] . following oral administration of levalbuterol hcl to pregnant rabbits, there was no evidence of teratogenicity at doses up to 25 mg/kg/day [approximately 750 times the maximum recommended human daily inhalation d

United States - English - NLM (National Library of Medicine)

proficient rx lp - levalbuterol tartrate (unii: ads4i3e22m) (levalbuterol - unii:edn2nbh5ss) - levalbuterol 45 ug - levalbuterol tartrate hfa inhalation aerosol is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 4 years of age and older with reversible obstructive airway disease. levalbuterol tartrate hfa inhalation aerosol is contraindicated in patients with a history of hypersensitivity to levalbuterol, racemic albuterol, or any other component of levalbuterol tartrate hfa inhalation aerosol. reactions have included urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema. teratogenic effects: pregnancy category c there are no adequate and well-controlled studies of levalbuterol tartrate hfa inhalation aerosol in pregnant women. because animal reproduction studies are not always predictive of human response, levalbuterol tartrate hfa inhalation aerosol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. rare instances of congenital anomalies, including cleft palate and limb defects, were reported in

United States - English - NLM (National Library of Medicine)

mylan institutional inc. - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol 2 mg - albuterol tablets are indicated for the relief of bronchospasm in adults and children 6 years of age and older with reversible obstructive airway disease. albuterol tablets are contraindicated in patients with a history of hypersensitivity to albuterol, or any of its components.

United States - English - NLM (National Library of Medicine)

american health packaging - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol 2 mg - albuterol tablets are indicated for the relief of bronchospasm in adults and children 6 years of age and older with reversible obstructive airway disease. albuterol tablets are contraindicated in patients with a history of hypersensitivity to albuterol, or any of its components.

United States - English - NLM (National Library of Medicine)

akorn - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol 2 mg in 5 ml - albuterol sulfate syrup is indicated for the relief of bronchospasm in adults and children 2 years of age and older with reversible obstructive airway disease. albuterol sulfate syrup is contraindicated in patients with a history of hypersensitivity to albuterol or any of its components.

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol 2 mg - albuterol tablets are indicated for the relief of bronchospasm in adults and children 6 years of age and older with reversible obstructive airway disease. albuterol tablets are contraindicated in patients with a history of hypersensitivity to albuterol, or any of its components.

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol 2 mg - albuterol tablets are indicated for the relief of bronchospasm in adults and children 6 years of age and older with reversible obstructive airway disease. albuterol tablets are contraindicated in patients with a history of hypersensitivity to albuterol, or any of its components.